がんワクチンの世界市場・パイプライン分析

◆英語タイトル:Cancer Vaccines Market, Pipeline Analysis Report 2020
◆商品コード:DPI20AG06
◆発行会社(リサーチ会社):DPI Research
◆発行日:2020年6月
◆ページ数:115
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,590 ⇒換算¥166,950見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,490 ⇒換算¥261,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDPI Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DPI Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、がんワクチンの世界市場について、エグゼクティブサマリー、イントロダクション、がんワクチンのメカニズム、市場規模・予測、市場成長・阻害要因、がんワクチン研究への資金調達、規制環境-がんワクチン承認プロセス、主要企業分析、新興企業分析など、調査・分析を行い、今後の市場展望をまとめております。
・エグゼクティブサマリー
・イントロダクション
・がんワクチンのメカニズム
・市場規模・予測
・市場成長・阻害要因
・がんワクチン研究への資金調達
・規制環境-がんワクチン承認プロセス
・主要企業分析
・新興企業分析
【レポートの概要】

“Global Cancer Vaccines market size is expected to surpass US$ 8.5 Billion by 2025”

Report Scope:
• Detailed Insights of the Introduction to Cancer Vaccines and Mechanism of Cancer Vaccines
• The Market Size of the Global Cancer Vaccines Market with Five Years Forecast
• The Market Size of the 4 Leading Cancer Vaccines with Five Years Forecast
• Provides Comprehensive Insights on the Funding of the Cancer Vaccines Research
• Investigates the Key Growth Drivers and Restraints of the Global Cancer Vaccines Market
• Provides Key Trends with Respect to Collaboration Deals, Merger & Acquisitions, Partnership Deals, and Licensing Agreement
• Detailed Insights of the Regulatory Framework Including the Approval Process and an Overview of the Regulatory Authorities in the United States, EU, and Japan
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Sales Value Analysis, and Recent Development
• An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

“Cancer Vaccines Market, Pipeline Analysis Report, 2020” provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market. The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the global cancer vaccines market. The report provides historical market data for 2015 – 2019, and forecasts from 2020 till 2025.

The report contains a granular evaluation of the prevailing enterprise conditions, market demands, reveal facts in the marketplace, revenues, and offers forecasts through 2025. The report presents clear perception into current and future developments of the global cancer vaccines market.

The report explores detailed insights into the introduction to cancer vaccines and the mechanism of cancer vaccines. The report additionally provides a detailed evaluation of the leading 4 key marketed cancer vaccines market assessments globally, data from 2015 to 2019, and forecasts to 2025. The report reviews a clear insight into the funding of the cancer vaccines studies. The report additionally investigates special insights about the regulatory landscape which include the approval system and an overview of the regulatory authorities in the United States, EU, and Japan.

Key developments of collaboration, partnerships, merger & acquisition, and licensing settlement are analyzed with details. The report additionally examines the principle marketplace growth drivers and restraining forces and also offers an all-round future outlook.

The report concludes with the profiles of the key players in the global cancer vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, vaccines revenue analysis, and recent development.

Other emerging players are making novel era-based vaccines that are in all possibility to have an effect on the market share during the forecast duration. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with the current stage of clinical evaluation, vaccines target, platform technology, and recent developments.

The following 4 leading vaccines of the global cancer vaccines market are detailed with market size and five-year forecast:
• Gardasil/Gardasil 9
• Cervarix
• Provenge
• Imlygic

The foremost companies dominating this market for its products, offerings, and non-stop product trends are:
• Amgen
• Merck & Co., Inc
• GlaxoSmithKline (GSK)
• Dendreon Pharmaceuticals (Sanpower Group)
• GeoVax,Inc
• Moderna, Inc
• Flow Pharma, Inc
• Polynoma LLC
• IO Biotech
• OncoPep, Inc
• Medigen, Inc
• ViciniVax
• ImmuneTune
• Treos Bio Limited
• EpiThany
• CureVac AG
• DCprime
• Vaximm AG
• AdaptVac
• MimiVax LLC
• Agenus, Inc
• AlphaVax, Inc
• Genexine
• GlobeImmune, Inc
• Ubivac, Inc
• Vaccinogen, Inc
• Genocea Biosciences, Inc
• Northwest Biotherapeutics, Inc
• OncBioMune Pharmaceuticals, Inc
• Inovio Pharmaceuticals, Inc
• Enochian Biosciences
• Eu Biologics Co., Ltd.
• EVOQ Therapeutics
• Heat Biologics, Inc
• Scancell Holdings PLC
• Anixa Biosciences, Inc
• PDC*line Pharma
• Elios Therapeutics, LLC
• OSE Immunotherapeutics

The Report Helps Solution the Following Questions:
• What is the current size of the overall global cancer vaccines market? How much will this market be worth from 2020 to 2025?
• What are the key marketed cancer vaccines? What are their revenue potentials to 2025?
• What are the main drivers and restraints in the global cancer vaccines market?
• What are the major deals happenings in the global cancer vaccines market?
• Who are the top market players and what are their happenings, vaccines revenue, current developments, and scenarios?
• What are some of the most prominent cancer vaccines currently in clinical development? What are their happenings, platform technology, and current developments?

【レポートの目次】

1. Executive Summary

2. Introduction to Cancer Vaccines

3. Mechanism of Cancer Vaccines

4. Global Cancer Vaccines Market Size and Forecast (2015 – 2025)

5. Key Marketed Cancer Vaccines Market Value (2015 – 2025)
5.1 Gardasil/Gardasil 9
5.2 Cervarix
5.3 Provenge
5.4 Imlygic

6. Key Market Drivers and Inhibitors of the Cancer Vaccines Market
6.1 Key Market Drivers
6.2 Key Market Inhibitors

7. Funding in the Cancer Vaccines Research

8. Major Deals and Agreement Happenings in the Cancer Vaccines Market
8.1 Collaboration Deals
8.2 Licensing Agreement
8.3 Partnership Deals
8.4 Merger & Acquisitions

9. Regulatory Environment – Cancer Vaccines Approval Process
9.1 United States
9.2 Europe
9.3 Japan

10. Key Players Analysis
10.1 Merck & Co., Inc.
10.1.1 Business Overview
10.1.2 Vaccines Portfolio
10.1.3 Recent Development
10.2 GlaxoSmithKline (GSK)
10.2.1 Business Overview
10.2.2 Vaccines Portfolio
10.3 Dendreon Pharmaceuticals (Sanpower Group)
10.3.1 Business Overview
10.3.2 Vaccines Portfolio
10.3.3 Recent Development
10.4 Amgen
10.4.1 Business Overview
10.4.2 Vaccines Portfolio
10.4.3 Recent Development

11. Emerging Players Analysis
11.1 Genocea Biosciences,Inc
11.1.1 Business Overview
11.1.2 Promising Cancer Vaccines in the Clinical Development
11.1.3 Recent Development
11.2 GeoVax, Inc
11.2.1 Business Overview
11.2.2 Promising Cancer Vaccines in the Clinical Development
11.2.3 Recent Development
11.3 Moderna, Inc
11.3.1 Business Overview
11.3.2 Promising Cancer Vaccines in the Clinical Development
11.3.3 Recent Development
11.4 Northwest Biotherapeutics, Inc
11.4.1 Business Overview
11.4.2 Promising Vaccines in the Clinical Development
11.4.3 Recent Development
11.5 OncBioMune Pharmaceuticals, Inc
11.5.1 Business Overview
11.5.2 Promising Vaccines in the Clinical Development
11.5.3 Recent Development
11.6 Inovio Pharmaceuticals, Inc
11.6.1 Business Overview
11.6.2 Promising Cancer Vaccines in the Clinical Development
11.6.3 Recent Development
11.7 Enochian Biosciences
11.7.1 Business Overview
11.7.2 Promising Cancer Vaccines in the Clinical Development
11.8 Flow Pharma, Inc
11.8.1 Business Overview
11.8.2 Promising Cancer Vaccines in the Clinical Development
11.8.3 Recent Development
11.9 Polynoma LLC
11.9.1 Business Overview
11.9.2 Promising Cancer Vaccines in the Clinical Development
11.9.3 Recent Development
11.10 IO Biotech
11.10.1 Business Overview
11.10.2 Promising Cancer Vaccines in the Clinical Development
11.10.3 Recent Development
11.11 Eu Biologics Co., Ltd.
11.11.1 Business Overview
11.11.2 Promising Cancer Vaccines in the Clinical Development
11.12 OncoPep, Inc
11.12.1 Business Overview
11.12.2 Promising Cancer Vaccines in the Clinical Development
11.12.3 Recent Development
11.13 Medigen, Inc
11.13.1 Business Overview
11.13.2 Promising Cancer Vaccines in the Clinical Development
11.14 EVOQ Therapeutics
11.14.1 Business Overview
11.14.2 Promising Cancer Vaccines in the Clinical Development
11.15 Heat Biologics, Inc
11.15.1 Business Overview
11.15.2 Promising Cancer Vaccines in the Clinical Development
11.15.3 Recent Development
11.16 ViciniVax
11.16.1 Business Overview
11.16.2 Promising Cancer Vaccines in the Clinical Development
11.17 ImmuneTune
11.17.1 Business Overview
11.17.2 Promising Cancer Vaccines in the Clinical Development
11.18 Elios Therapeutics LLC
11.18.1 Business Overview
11.18.2 Promising Cancer Vaccines in the Clinical Development
11.18.3 Recent Development
11.19 Treos Bio Limited
11.19.1 Business Overview
11.19.2 Promising Cancer Vaccines in the Clinical Development
11.19.3 Recent Development
11.20 Scancell Holdings PLC
11.20.1 Business Overview
11.20.2 Promising Cancer Vaccines in the Clinical Development
11.20.3 Recent Development
11.21 EpiThany
11.21.1 Business Overview
11.21.2 Promising Cancer Vaccines in the Clinical Development
11.21.3 Recent Development
11.22 CureVac AG
11.22.1 Business Overview
11.22.2 Promising Cancer Vaccines in the Clinical Development
11.22.3 Recent Development
11.23 DCprime
11.23.1 Business Overview
11.23.2 Promising Cancer Vaccines in the Clinical Development
11.23.3 Recent Development
11.24 Vaximm AG
11.24.1 Business Overview
11.24.2 Promising Cancer Vaccines in the Clinical Development
11.24.3 Recent Development
11.25 Anixa Biosciences, Inc
11.25.1 Business Overview
11.25.2 Promising Cancer Vaccines in the Clinical Development
11.25.3 Recent Development
11.26 AdaptVac
11.26.1 Business Overview
11.26.2 Promising Cancer Vaccines in the Clinical Development
11.26.3 Recent Development
11.27 PDC*line Pharma
11.27.1 Business Overview
11.27.2 Promising Cancer Vaccines in the Clinical Development
11.27.3 Recent Development
11.28 MimiVax LLC
11.28.1 Business Overview
11.28.2 Promising Cancer Vaccines in the Clinical Development
11.28.3 Recent Development
11.29 Agenus, Inc
11.29.1 Business Overview
11.29.2 Promising Cancer Vaccines in the Clinical Development
11.30 AlphaVax, Inc
11.30.1 Business Overview
11.30.2 Promising Cancer Vaccines in the Clinical Development
11.31 Genexine
11.31.1 Business Overview
11.31.2 Promising Cancer Vaccines in the Clinical Development
11.31.3 Recent Development
11.32 GlobeImmune, Inc
11.32.1 Business Overview
11.32.2 Promising Cancer Vaccines in the Clinical Development
11.33 Ubivac, Inc
11.33.1 Business Overview
11.33.2 Promising Cancer Vaccines in the Clinical Development
11.34 Vaccinogen, Inc
11.34.1 Business Overview
11.34.2 Promising Cancer Vaccines in the Clinical Development
11.35 OSE Immunotherapeutics
11.35.1 Business Overview
11.35.2 Promising Cancer Vaccines in the Clinical Development
11.35.3 Recent Development

List of Tables:

Table 8–1: Collaboration Deals in the Cancer Vaccines Market
Table 8–2: Licensing Agreement in the Cancer Vaccines Market
Table 8–3: Partnership Deals in the Cancer Vaccines Market
Table 8–4: Merger & Acquisitions in the Cancer Vaccines Market
Table 9–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 11–1: Genocea Biosciences, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–2: GeoVax, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–3: Moderna, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–4: Northwest Biotherapeutics, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–5: OncBioMune Pharmaceuticals, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–6: Inovio Pharmaceuticals, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–7: Enochian Biosciences Promising Cancer Vaccines in the Clinical Development
Table 11–8: Flow Pharma, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–9: Polynoma LLC Promising Cancer Vaccines in the Clinical Development
Table 11–10: IO Biotech Promising Cancer Vaccines in the Clinical Development
Table 11–11: Eu Biologics Co., Ltd. Promising Cancer Vaccines in the Clinical Development
Table 11–12: OncoPep Promising Cancer Vaccines in the Clinical Development
Table 11–13: Medigen, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–14: EVOQ Therapeutics Promising Cancer Vaccines in the Clinical Development
Table 11–15: Heat Biologics, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–16: Vicinivax Promising Cancer Vaccines in the Clinical Development
Table 11–17: ImmuneTune Promising Cancer Vaccines in the Clinical Development
Table 11–18: Elios Therapeutics Promising Cancer Vaccines in the Clinical Development
Table 11–19: Treos Bio Limited Promising Cancer Vaccines in the Clinical Development
Table 11–20: Scancell Holdings PLC Promising Cancer Vaccines in the Clinical Development
Table 11–21: EpiThany Promising Cancer Vaccines in the Clinical Development
Table 11–22: CureVac AG Promising Cancer Vaccines in the Clinical Development
Table 11–23: DCprime Promising Cancer Vaccines in the Clinical Development
Table 11–24: Vaximm AG Promising Cancer Vaccines in the Clinical Development
Table 11–25: Anixa Biosciences, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–26: AdaptVac Promising Cancer Vaccines in the Clinical Development
Table 11–27: PDC*line Pharma Promising Cancer Vaccines in the Clinical Development
Table 11–28: MimiVax LLC Promising Cancer Vaccines in the Clinical Development
Table 11–29: Agenus, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–30: AlphaVax Promising Cancer Vaccines in the Clinical Development
Table 11–31: Genexine Promising Cancer Vaccines in the Clinical Development
Table 11–32: GlobeImmune, Inc Promising Cancer Vaccines in the Clinical Development
Table 11–33: Ubivac Promising Cancer Vaccines in the Clinical Development
Table 11–34: Vaccinogen Promising Cancer Vaccines in the Clinical Development
Table 11–35: OSE Immunotherapeutics Promising Cancer Vaccines in the Clinical Development

List of Figures:

Figure 4–1: Global Cancer Vaccines Market Size (Million US$), 2015 – 2019
Figure 4–2: Global Cancer Vaccines Market Forecast (Million US$), 2020 – 2025
Figure 5–1: Gardasil/Gardasil 9 Market Value Analysis (Million US$), 2015 – 2019
Figure 5–2: Gardasil/Gardasil 9 Market Value Forecast (Million US$), 2020 – 2025
Figure 5–3: Cervarix Market Value Analysis (Million US$), 2015 – 2019
Figure 5–4: Cervarix Market Value Forecast (Million US$), 2020 – 2025
Figure 5–5: Provenge Market Value Analysis (Million US$), 2015 – 2019
Figure 5–6: Provenge Market Value Forecast (Million US$), 2020 – 2025
Figure 5–7: Imlygic Market Value Analysis (Million US$), 2016 – 2019
Figure 5–8: Imlygic Market Value Forecast (Million US$), 2020 – 2025


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[がんワクチンの世界市場・パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆